European Medicines Agency Confirms Accelerated Assessment Procedure for Trogarzo™

Jul 31, 2018
PDF Version
Supporting Materials:

Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) will review the application for marketing authorization of TrogarzoTM (ibalizumab-uiyk) injection under the accelerated assessment procedure.